• About us

    The German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL) is an association of 29 leading university and non-university institutions dedicated to pulmonary research. The DZL coordinates and conducts basic scientific, disease-oriented, and patient-centered research in the field of lung disease meeting the highest international standards. 
    Learn more about DZL
  • Translational Research

    The road of a finding from laboratory research to medical innovation is often long. Only a small fraction of the newly discovered active substances makes it to the practical application on patients, with an average development period of about 15 years.
    Learn more about Translational Research
  • DZL Academy

    The main goal of the DZL Academy is to support the careers of students and doctoral candidates in medicine and human/life sciences with reference to clinical, translational and basic lung research
    More about DZL Academy
  • Our Mission

    Was treibt die Forscher und Ärzte im Deutschen Zentrum für Lungenforschung an? Was ist unser Ziel und was macht uns aus? Wir nehmen Sie mit und geben Ihnen einen Einblick in die tägliche Arbeit an unseren fünf Standorten in Deutschland.
    Watch our Image Video

DZL News

DZL Funds Four More Clinical Trials – Significant Contribution to Translational Research

Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be funded as of 2021.

Read more
Pirfenidone Could Also Help Treat Other Fibrotic Lung Diseases – Not Only IPF

To date, pirfenidone has only been used for the treatment of Idiopathic Pulmonary Fibrosis (IPF). DZL researchers have now investigated whether this drug may also help in the treatment of other progressive fibrotic interstitial lung diseases – successfully.

Read more
Extended analysis of tumour DNA in patients’ blood could improve therapy control in lung cancer

Analysing copy number variations (CNVs) of tumour DNA extracted from blood samples of patients with ALK-positive non-small-cell lung cancer can provide valuable information on therapy response and has the potential to improve therapy control.

Read more
To DZL news overview